10 Best Income Stocks To Buy For 2014

Fear and worry about China's economy and financial system appears to be taking its toll on China's leading insurers, and MoneyShow's Jim Jubak, thinks that's why it's important to look for a financial company in China that's firing on all cylinders.

Ping An Insurance Group ((PNGAY) in New York and (HK:2318) in Hong Kong) kicked off earnings reporting season for China�� big insurance companies yesterday. Ping An, China�� second largest insurer, reported a 40.3% gain in net income for 2013.

That 40% gain in net income is likely to be among the lower increases reported by China�� insurance companies in the next few weeks. The average growth in net income among insurers expected by analysts is 92%. I think that makes it worthwhile holding the best of these insurers��uch as Ping An and China Life (LFC), a member of my Jubak�� Picks portfolio, for these earnings reports, even though the systemic stress��nd thus risk��n China�� financial system is rising.

Top Rising Companies To Watch In Right Now: Franklin Electric Co. Inc.(FELE)

Franklin Electric Co., Inc., together with its subsidiaries, engages in the design, manufacture, and distribution of groundwater and fuel pumping systems. It operates in two segments, Water Systems and Fueling Systems. The Water Systems segment provides motors, pumps, electronic controls, and related parts and equipment primarily for use in groundwater, wastewater, and fuel transfer applications. Its motors and pumps are used principally for pumping fresh water and wastewater in various residential, agricultural, and industrial applications. This segment also offers electronic drives and controls for the motors, which control functionality and provide protection from various hazards, such as electric surges, over-heating, or dry wells and tanks. The Fueling Systems segment provides pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment primarily for use in submersible fueling system applications. It also integrates and sells motors and electronic controls produced by the Water Systems segment. The company sells its products and related equipment to specialty distributors, original equipment manufacturers, industrial and petroleum equipment distributors, and oil and utility companies through its sales force and independent manufacturing representatives primarily in the United States, Europe, South Africa, Brazil, Mexico, and China. Franklin Electric Co., Inc. was founded in 1944 and is headquartered in Bluffton, Indiana.

Advisors' Opinion:

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Franklin Electric (Nasdaq: FELE  ) .

• [By Seth Jayson]

  Margins matter. The more Franklin Electric (Nasdaq: FELE  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Franklin Electric's competitive position could be.

10 Best Income Stocks To Buy For 2014: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Mylan (NASDAQ: MYL) got a boost, shooting up 2.49 percent to $51.10 on reports of interest in Sweden's Meda.

  IMS Health Holdings (NYSE: IMS) shares were also up, gaining 17.40 percent to $23.45 in their debut on the NYSE.

• [By Ben Levisohn]

  That decision has helped make Allergan the top performing pharmaceutical stock in the S&P 500. Its shares have gained 4.3% to $108.18, today at 2:32 p.m., besting Merck’s (MRK) 1.2% rise to $49.36, Mylan’s (MYL) 1.1% advance to $42.98, Hospira’s (HSP) 0.7% increase to $41.34 and Eli Lily’s (LLY) 0.6% rise to $50.42.

• [By Seth Jayson]

  Mylan (Nasdaq: MYL  ) reported earnings on May 2. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Mylan missed estimates on revenues and met expectations on earnings per share.

10 Best Income Stocks To Buy For 2014: Norwegian Cruise Line Holdings Ltd (NCLH)

Norwegian Cruise Line Holdings Ltd., incorporated on February 21, 2011, is a global cruise line operator, offering cruise experiences for travelers with a variety of itineraries in North America (including Alaska and Hawaii), the Mediterranean, the Baltic, Central America, Bermuda and the Caribbean. The Company offers a variety of cruises ranging from one day to three weeks. During the year ended December 31, 2010, the Company docked at over 125 ports worldwide, with itineraries originating from 17 ports of which ten were in North America. In June 2010, the Company took delivery of its largest cruise ship, Norwegian Epic (4,100 Berths), which offers 21 dining options.

The Company�� ships have passenger amenities, including up to 21 dining options together with hundreds of private balcony cabins on each ship. As of March 31, 2011, 48% of its cabins have private balconies. Five of its ships offer a complex of private courtyard villas, each with up to approximately 570 square feet, which provide personal butler service and access to a private courtyard area with private pools, sundeck, hot tubs, and fitness center. In addition, six of its ships have garden villas with up to 6,694 square feet. These garden villas offer three separate bedroom areas, spacious living and dining room areas, as well as around-the-clock, on-call butler and concierge service.

Norwegian Epic offers its passengers itineraries to the western and eastern Caribbean, as well as Europe. The ship offers its customers an aqua park, sports complex, two three-lane bowling alleys and its two-story Wii Wall. In addition, the ship features a spa facility and fitness center with more than 31,000 square feet. Entertainment is offered aboard Norwegian Epic with the addition of entertainment choices, including Blue Man Group, Cirque Dreams & Dinner, Legends in Concert and Nickelodeon at Sea. It offers entertainment in its jazz and blues club and its comedy club features the comedy troupe, The Second City.

Advisors' Opinion:

• [By Traders Reserve]

  Norwegian Cruise Lines (NCLH) might be the ultimate toy for these managers and the timing looks perfect. The travel space is red hot. Consumer and business travelers are filling up capacity in a big way. Profits are growing and at a fast pace and yet shares of Norwegian trade for a low multiple of earnings. Analysts expect the company to grow profits by 63% in 2014.

• [By Christopher Palmeri]

  Norwegian Cruise Line Holdings Ltd. (NCLH)�� three largest investors filed to sell about $600 million of their stakes after a run-up in the share price since January�� initial public offering.

• [By Ben Levisohn]

  And what’s good for Carnival should also be good for Royal Caribbean Cruises (RCL), which also got an upgrade, Norwegian Cruise Line Holdings�(NCLH), which Farley and Kocharyan label their top pick. They explain:

10 Best Income Stocks To Buy For 2014: Retail Opportunity Investments Corp.(ROIC)

Retail Opportunity Investments Corp., a real estate investment trust (REIT), engages in the acquisition, ownership, and management of necessity-based community and neighborhood shopping centers in the eastern and western regions of the United States. As of December 31, 2011, its portfolio consisted of 30 owned retail properties totaling approximately 3.2 million square feet of gross leasable area. The company has elected to be taxed as a REIT, for U.S. federal income tax purposes. The company is based in White Plains, New York.

Advisors' Opinion:

• [By nnnguyen1221]

  Return on Invested Capital (ROIC):

  Return on Invested Capital (ROIC) combines the best in both worlds by measuring the return on all capital invested in the firm (both debt and equity). Does the company show a consistently high return on total capital (above 12%)?

• [By David Trainer]

  Over the past few years, SWK has demonstrated little ability to grow NOPAT organically. Instead, the company has relied on big acquisitions to fuel growth. This strategy is unsustainable because the company cannot indefinitely pump more capital into the business while getting back proportionally less cash flow (NOPAT). That strategy leads to declining ROICs, which is what the company is doing now. Figure 1 contrasts SWK's rising NOPAT with its declining return on invested capital (ROIC). Investors should focus on the bottom line, which is ROIC, not the top line revenues or earnings because those metrics ignore the amount of invested capital used to generate them.

10 Best Income Stocks To Buy For 2014: Cardinal Health Inc. (CAH)

Cardinal Health, Inc. operates as a healthcare solutions company that provides health care products and services. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, over-the-counter healthcare, specialty pharmaceutical, and consumer products to retail customers, hospitals, and alternate care providers in the United States and Puerto Rico. This segment also operates nuclear pharmacies and cyclotron facilities that prepare and deliver radiopharmaceuticals for use in nuclear imaging and other procedures in hospitals and clinics; offers third-party logistics support services; franchises retail pharmacies under the Medicine Shoppe and Medicap brands; and provides pharmacy and pharmaceutical repackaging services, as well as other services comprising distribution, inventory management, data/reporting, new product launch support, and contract and chargeback administration. The Medical segment distributes a range of medical, surgical, and laboratory products to hospitals, surgery centers, laboratories, physician offices, and other healthcare providers. This segment also develops, manufactures, and sources medical and surgical products, including sterile and non-sterile procedure kits; single-use surgical drapes, gowns, and apparel; exam and surgical gloves; and fluid suction and collection systems. Its medical and surgical products are sold directly or through third-party distributors in the United States, Canada, Europe, South America, and the Asia/Pacific region. The company was founded in 1979 and is headquartered in Dublin, Ohio.

Advisors' Opinion:

• [By Dividends4Life]

  Linked here is a detailed quantitative analysis of Cardinal Health, Inc. (CAH). Below are some highlights from the above linked analysis:

  Company Description: Cardinal Health Inc. is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies and related products to a broad range of health care customers.

• [By Ben Levisohn]

  Overvalued companies include MWI Veterinary (MWIV) and�Stericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but calls�Aratana (PETX) a “hidden gem.”

• [By Victor Selva]

  The company has a very attractive current ratio of 33.03% which is higher than its comps: Becton Dickinson & Co (BDX), Cardinal Health Inc (CAH), Cooper Companies (COO) and Luxottica Group S.p.A. (LUX).

• [By Sure Dividend]

  Health care will be necessary until we find a cure for everything. There is a less than infinitesimal chance of us finding a cure for everything in the next several decades. The following companies are Dividend Aristocrats whose revenue is generated primarily in the health care sector:

  HCP, Inc. (HCP) AbbVie (ABBV) Johnson & Johnson (JNJ) Abbott Laboratories (ABT) Walgreen (WAG) Medtronic (MDT) Becton Dickinson (BDX) Cardinal Health (CAH) C.R. Bard (BCR)

  Not to be outdone by the food and beverage industry (or perhaps due to negative health effects from the food and beverage industry), the health care industry counts nine Dividend Aristocrats in its ranks. They operate in more diverse lines of business than the food companies. HCP is a REIT that focuses on health care properties. C.R. Bard, Medtronic, and Becton Dickinson manufacture and distribute health care devices and supplies. Abbott Laboratories and Johnson & Johnson (and to a lesser extent, Cardinal Health) are well-diversified health care businesses. AbbVie was recently spun-off from Abbott Laboratories (notice the vaguely similar names), and is a pharmaceutical company.

10 Best Income Stocks To Buy For 2014: Rigel Pharmaceuticals Inc.(RIGL)

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its product development programs include R788, which completed a phase 2 clinical trial for the treatment of rheumatoid arthritis; and is in phase 2 clinical trials for B-cell lymphoma, T-cell lymphoma, immune thrombocytopenia purpura, and certain solid tumors. The company?s product development programs also comprise R343, which is in phase 1b clinical trial for the treatment of asthma. In addition, its preclinical programs include oral JAK3 inhibitor program for research in the area of immunology/inflammation; adiponectin mimetics for the treatment of type 2 diabetes mellitus and other potential indications; and muscle atrophy program for muscle homeostasis. Further, the company is evaluating R763/AS703569 compound in its aurora kinase inhibition program targeting cancer cell proliferation. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB; Pfizer, Inc.; and Daiichi Pharmaceuticals Co., Ltd. The company was founded in 1996 and is based in South San Francisco, California.

Advisors' Opinion:

• [By Keith Speights]

  Pain-medication pain
  Rigel Pharmaceuticals (NASDAQ: RIGL  ) experienced pain this week, resulting from its drug intended to help rheumatoid arthritis patients suffer less pain. Shares fell almost 23%.

• [By Max Macaluso, Ph.D.]

  Early Tuesday morning, Rigel Pharmaceuticals� (NASDAQ: RIGL  ) and its now-ex-partner, AstraZeneca (NYSE: AZN  ) , reported late-stage clinical trial results for the experimental rheumatoid arthritis drug Fostamatinib. In the following video, health-care analyst Max Macaluso discusses why Rigel dropped 18% after the news was released and the risks that lie ahead for Rigel Pharmaceuticals.

• [By Sean Williams]

  What: Shares of Rigel Pharmaceuticals (NASDAQ: RIGL  ) , a clinical-stage small molecule drug company focused on inflammatory and autoimmune disorders, dropped as much as 21% after the company resumed full responsibility for its rheumatoid arthritis pill, Fostamatinib, and reported topline data from two late-stage studies involving the drug.

• [By Sean Williams]

  It wasn't nearly as exciting a week for Rigel Pharmaceuticals (NASDAQ: RIGL  ) , which regained full rights to rheumatoid arthritis pill Fostamatinib from AstraZeneca�on Tuesday. The pair actually reported a statistically significant ACR20 response rate at 24 weeks in two trials, but the data isn't expected to be conclusive enough to gain FDA approval. AstraZeneca, not wanting to spend any more on the program, took a $140 million charge and returned all licensing back to Rigel. With the prospect of high trial costs and a drug which did well, but perhaps not well enough to compete with competition already on the market, Rigel is now in a tough position and is worth avoiding at all costs.

10 Best Income Stocks To Buy For 2014: Abraxas Petroleum Corp (AXAS)

Abraxas Petroleum Corporation is an independent energy company primarily engaged in the acquisition, exploitation, development and production of oil and gas in the United States and Canada. As of December 31, 2011, the Company�� estimated net proved reserves were 29.0 million barrels of oil equivalent (MMBoe), (including reserves attributable to its 34.7% equity interest in the proved reserves of Blue Eagle), of which 53% were classified as proved developed, 54% were oil and natural gas liquids (NGL��) and 94% by PV-10 were operated. Its daily net production during the year ended December 31, 2011, was 3,484 barrels of oil equivalent per day, of which 45% was oil or liquids. Its oil and gas assets are located in four operating regions in the United States, the Rocky Mountain, Mid-Continent, Permian Basin and onshore Gulf Coast, and in the province of Alberta, Canada.

The Company�� properties in the Rocky Mountain region are located in the Williston Basin of North Dakota and Montana and in the Green River, Powder River and Unita Basins of Wyoming and Utah. In this region, its wells produce oil and gas from various reservoirs, including the Niobrara, Turner, Bakken and Three Forks formations. Well depths range from 7,000 feet down to 14,000 feet. The Company�� properties in the Mid-Continent region are primarily located in the Arkoma Basin and principally produce gas from the Hartshorne coals at 3,000 feet. Its properties in the Permian Basin region are primarily located in two sub-basins, the Delaware Basin and the Eastern Shelf. In the Delaware Basin, its wells are located in Pecos, Reeves, and Ward Counties, Texas and produce oil and gas from multiple stacked formations from the Bell Canyon at 5,000 feet down to the Ellenburger at 16,000 feet.

In the Eastern Shelf, its wells are principally located in Coke, Scurry, Midland, Mitchell and Nolan Counties, Texas and produce oil and gas from the Strawn Reef formation at 5,000 to 7,500 feet and oil from the shallower Clea! rfork formation at depths ranging from 2,300 to 3,300 feet. The Company�� properties in the onshore Gulf Coast region are located along the Edwards trend in DeWitt and Lavaca Counties, Texas and in the Portilla field in San Patricio County, Texas. In the Edwards trend, its wells produce gas from the Edwards formation at a depth of 14,000 feet and in the Portilla field, its wells produce oil and gas from the Frio sands and the deeper Vicksburg from depths of approximately 7,000 to 9,000 feet. In addition, the Company also owns a 34.7% equity interest in a joint venture targeting the Eagle Ford in South Texas. Its properties in the province of Alberta, Canada are located in the Pekisko fairway and the Nordegg/Tomahawk area of Central Alberta.

As of December 31, 2011, the Company leased approximately 20,835 net acres, primarily in counties located on the Nesson Anticline and in areas west, including Rough Rider and Lewis & Clark in North Dakota and in Sheridan County, Montana, which are prospective for the Bakken and Three Forks formations. During the year ended December 31, 2011, the Company drilled two operated wells and participated in an additional 19 gross (1.0 net) non-operated wells. In July 2011, Abraxas purchased a used Oilwell 2000 horsepower diesel electric drilling rig. In August 2010, the Company formed a joint venture, Blue Eagle, with Rock Oil to develop its acreage in the Eagle Ford Shale play. As of December 31, 2011, the Company owned a 34.7% interest in Blue Eagle. During 2011, Blue Eagle drilled, completed or participated in three gross (2.4 net) wells and added approximately 3,800 net acres to its holdings, principally in McMullen County, Texas.

As of December 31, 2011, the Company leased a total of approximately 20,720 gross (17,800 net) acres in the southern Powder River Basin, of which 17,800 gross (15,700 net) acres were located in the Brooks Draw field of Converse and Niobrara Counties, Wyoming. In addition, it owns approximately 2,100 net acres in sout! hern Camp! bell County, Wyoming which are held by production and are near the Crossbow field operated by EOG Resources, Inc. and other recent horizontal activity. As of December 31, 2011, the Company leased 6,880 net acres in western Alberta. In 2011, it drilled or completed six gross (6 net) wells in the Twining area. In the emerging southern Alberta Basin Bakken play of Toole and Glacier Counties, Montana, the Company leased approximately 10,000 gross/net acres under long-term leases or direct mineral ownership. As of December 31, 2011, it leased approximately 5,600 gross/net acres in Nolan County, Texas. In 2011, the Company drilled three wells in the Spires Ranch offsetting the prolific Nena Lucia field.

Advisors' Opinion:

• [By Rick Munarriz]

  Friday
  The market is typically quiet on Friday, but that's certainly not the case during earnings season. Abraxas Petroleum (NASDAQ: AXAS  ) checks in with its latest quarterly results on Friday morning. The San Antonio-based crude oil and natural gas exploration and production company is expected to post breakeven results.

• [By Tyler Crowe]

  In the energy world, it's never much of a surprise when an oil company picks up natural gas assets or vice versa. But a coal company getting into the oil business? Now that's a rarity. This week, Natural Resources Partners (NYSE: NRP  ) �did just that. The company announced that it's taking a working interest in some of Abraxas Petroleums (NASDAQ: AXAS  ) assets in the Bakken. While the $35 million purchase was not that large, it's a rare case where a coal company branches out into other natural resources.�

• [By Lisa Levin] Related IIN Morning Market Movers Morning Market Losers Related AXAS Abraxas Petroleum Corp. (AXAS) in Focus: Stock Moves 6.4% Higher - Tale of the Tape Will Noble Energy Disappoint This Quarter? - Analyst Blog

  Intricon (NASDAQ: IIN) shares gained 33.98% to touch a new 52-week high of $6.23 after the company reported Q1 results.

• [By Rich Duprey]

  With steam coal prices continuing to be weak due to the inroads made by natural gas, Natural Resource Partners (NYSE: NRP  ) has decided if you can't beat 'em, join 'em. It announced Monday it is buying producing�oil and gas�properties located in the Williston Basin of North Dakota and Montana from�Abraxas Petroleum (NASDAQ: AXAS  ) for $35.3 million in cash.